Ignite Creation Date:
2024-05-06 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 1:53 PM
Study NCT ID:
NCT04706533
Status:
COMPLETED
Last Update Posted:
2023-10-31
First Post:
2021-01-08
Brief Title:
Michigan Medicine COVID-19 Cohort Clinical Characteristics Inflammatory Markers and Outcomes of Patients Hospitalized for COVID-19
Sponsor:
University of Michigan
Organization:
University of Michigan
Study Overview
Official Title:
Prospective Observational Study Examining Clinical Characteristics Inflammatory Markers Treatments and Outcomes of Patients Hospitalized for COVID-19 at the University of Michigan Healthcare System in Ann Arbor
Status:
COMPLETED
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
M2C2
Brief Summary:
To better understand the role of inflammation in COVID-19 we established the Michigan Medicine COVID-19 Cohort M2C2 M2C2 is a funded and ongoing cohort which has currently enrolled over 1500 adult patients 18 years with severe COVID-19 admitted at the University of Michigan The purpose of M2C2 is to define the in-hospital course of these patients and understand the role of inflammation as a determinant of organ injury and outcomes in COVID-19
Detailed Description:
The Michigan Medicine COVID-19 Cohort is a prospective observational cohort study of patients hospitalized specifically for COVID-19 at the University of Michigan Health System in Ann Arbor Medical records of all consecutive patients with a positive SARS-CoV-2 are reviewed and patients with confirmed SARS-CoV-2 infection but not primarily admitted for COVID-19 were excluded
Biologic samples of patients enrolled in M2C2 were collected and clinical characteristics including in-hospital outcomes were characterized in detail
Biomarkers measured include but not be limited to soluble urokinase plasminogen activator receptor suPAR high sensitive C reactive protein hs-CRP brain natriuretic protein BNP high sensitive troponin T hsTnT interleukin 6 IL-6 osteopontin a2-antiplasmin
Biologic samples of patients enrolled in M2C2 were collected and clinical characteristics including in-hospital outcomes were characterized in detail
Biomarkers measured include but not be limited to soluble urokinase plasminogen activator receptor suPAR high sensitive C reactive protein hs-CRP brain natriuretic protein BNP high sensitive troponin T hsTnT interleukin 6 IL-6 osteopontin a2-antiplasmin
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None